1. Home
  2. PLAB vs PHVS Comparison

PLAB vs PHVS Comparison

Compare PLAB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Photronics Inc.

PLAB

Photronics Inc.

HOLD

Current Price

$48.07

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$28.22

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLAB
PHVS
Founded
1969
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
PLAB
PHVS
Price
$48.07
$28.22
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$44.33
$41.82
AVG Volume (30 Days)
803.7K
203.5K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
9.09
N/A
EPS
0.74
N/A
Revenue
$535,276,000.00
N/A
Revenue This Year
$6.70
N/A
Revenue Next Year
$4.96
N/A
P/E Ratio
$69.43
N/A
Revenue Growth
18.77
N/A
52 Week Low
$16.59
$15.51
52 Week High
$52.79
$30.24

Technical Indicators

Market Signals
Indicator
PLAB
PHVS
Relative Strength Index (RSI) 59.48 51.80
Support Level $21.30 $24.55
Resistance Level N/A $29.82
Average True Range (ATR) 2.05 1.40
MACD 0.17 -0.05
Stochastic Oscillator 49.74 55.84

Price Performance

Historical Comparison
PLAB
PHVS

About PLAB Photronics Inc.

Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: